BACKGROUND A change in the pharmaceutical environment has occurred from previously only needing to convince regulators of a product's safety and efficacy to obtain marketing authorisation to now needing to satisfy the value perceptions of other stakeholders, including payers, to attain market access for products. There is thus the need to understand the concept of market access that may be defi...

The total global pharmaceutical market was estimated at around US $343 billion (bn) in 1999 and registered a 10% growth in 1999 compared to 6-7% p.a. in the past three years. The industry is characterised by high fragmentation with the top ten companies accounting for only around 36% of the prescription pharmaceutical market in 1998. However, consolidation in the industry has resulted in an inc...

healthcare and Ranbaxy have been bought by Abbott and Daiichi Sankyo, respectively.[3] Cipla, an indigenous company, lone with a market share of about 5.4% tops the list of top 10 companies in India. The increasing presence of foreign companies among the top pharmaceutical companies in India is may be due to a few buyouts which happened in the recent past. Daiichi Sankyo, a leading Japanese pha...

mation superhighway have brought the countries of the world closer. From a business perspective, the world is one marketplace. The American pharmaceutical industry has played a pioneering role in the development of the drug industry through in-depth, timely, and useful research and bulk manufacturing of drug products. Although the US pharmaceutical industry is enjoying the leadership position, ...

This paper is an in depth analysis of the influence that investment into research and development has on a firm’s profitability in the pharmaceutical industry in the United States. The pharmaceutical industry is chosen due to its high intensity of research and development expenditures. The top 16 companies in the pharmaceutical industry are analyzed through regression analysis. The argument mad...

Product liability is one of the fastest growing and most economically significant applications of tort law. Product liability actions against pharmaceutical companies are among the most widely publicized classes of suits in the United States and Europe, prompting pharmaceutical companies to lobby vigorously for tort reform. (Nace et al., 1997). The liability burden on pharmaceutical companies h...

This project considers the allocation of control rights between pharmaceutical and biotechnology firms. I find that allocations of rights are sensitive to the bargaining position of both firms. In addition, biotechnology firms entering their first alliance tend, on average, to relinquish more rights. I also explore if and when alliances begin to impact pharmaceutical firm shareholder value. On ...

This paper seeks to provide an economic perspective on the pharmaceutical industry, which has come under increasing criticism on a number of issues. In the main, that criticism amounts to a rather ineffective flailing at the supply side of the market for pharmaceutical products-much of it based on inaccurate perceptions-when a more productive policy would be to strengthen the hitherto weak and ...